SEC Company Response from Q (QCLS) — Dec 15, 2017
Q/C TECHNOLOGIES, INC. (QCLS) (CIK 0001321834)
Date: Dec. 15, 2017 · CIK: 0001321834 · Accession: 0001213900-17-013325
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-221746
Letter
AKERS BIOSCIENCES, INC.
GROVE ROAD
THOROFARE, NJ 08086
December 15, 2017
VIA EDGAR
U.S. Securities & Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, D.C. 20549
Attention: Irene Paik
Re: Akers Biosciences, Inc.
Registration Statement on Form S-1
File No. 333-221746
Ladies and Gentlemen:
In accordance with Rule 461 of the Securities Act of 1933, as amended, Akers Biosciences, Inc. (the “Company”) hereby respectfully requests that the effective date of the above-captioned Registration Statement (the “Filing”) be accelerated so that it will be declared effective at 5:00 p.m. Eastern Time on Monday, December 18, 2017, or as soon thereafter as possible.
* * * *
Very
Truly Yours,
Akers
Biosciences, Inc.
Show Raw Text
CORRESP
1
filename1.htm
AKERS
BIOSCIENCES, INC.
201
GROVE ROAD
THOROFARE,
NJ 08086
December
15, 2017
VIA
EDGAR
U.S.
Securities & Exchange Commission
Division
of Corporation Finance
100
F Street, N.E.
Washington,
D.C. 20549
Attention:
Irene Paik
Re:
Akers
Biosciences, Inc.
Registration
Statement on Form S-1
File
No. 333-221746
Ladies
and Gentlemen:
In
accordance with Rule 461 of the Securities Act of 1933, as amended, Akers Biosciences, Inc. (the “Company”) hereby
respectfully requests that the effective date of the above-captioned Registration Statement (the “Filing”) be accelerated
so that it will be declared effective at 5:00 p.m. Eastern Time on Monday, December 18, 2017, or as soon thereafter as possible.
*
* * *
Very
Truly Yours,
Akers
Biosciences, Inc.
/s/
John J. Gormally
John
J. Gormally
Chief
Executive Officer